^
    19h
    LINKER-MM8: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P2/3, N=0, Withdrawn, Regeneron Pharmaceuticals | N=1570 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    1d
    Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. (PubMed, Hemasphere)
    Patients receiving immunoglobulin replacement therapy had a 2.01 lower risk of infections Grade 3 or 4 and a 6.14 lower risk of death. Our findings demonstrate the efficacy of teclistamab in a heavily diseased and pretreated cohort with AL amyloidosis and highlight the necessity of a concomitant immunoglobulin replacement therapy.
    Clinical • Retrospective data • Journal
    |
    NPPB (Natriuretic Peptide B)
    |
    Tecvayli (teclistamab-cqyv)
    2d
    CAREMM-011: CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    2d
    64007957MMY2022: A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination withnPomalidomide Administered in Alternative Fashion in Participants with RRMM, whonReceived 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy (2025-522114-23-00)
    P1/2, N=35, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    lenalidomide • pomalidomide • Tecvayli (teclistamab-cqyv)
    3d
    Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=8, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=34 --> 8 | Not yet recruiting --> Terminated; Achieved the proof of concept
    Enrollment change • Trial termination
    3d
    A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body (clinicaltrials.gov)
    P1, N=63, Not yet recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial • First-in-human
    3d
    iFIT: Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (clinicaltrials.gov)
    P3, N=1226, Not yet recruiting, University of Leeds
    New P3 trial
    |
    IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    4d
    CAREMM-013: CM336-SOC for Dynamically High-Risk Multiple Myeloma Study (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    4d
    OM336 in Seropositive Autoimmune Diseases (clinicaltrials.gov)
    P1, N=39, Recruiting, Ouro Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV (clinicaltrials.gov)
    P2/3, N=17, Not yet recruiting, University of Illinois at Chicago
    New P2/3 trial
    |
    CD4 (CD4 Molecule)
    |
    Elrexfio (elranatamab-bcmm)
    8d
    CM336 for Active Sjogren's Syndrome Study (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Keymed Biosciences Co.Ltd
    New P1 trial
    8d
    ENLIGHT: A Phase II study of elranatamab in newly diagnosed systemic light-chain (AL) amyloidosis (ACTRN12626000704392)
    P2, N=10, Not yet recruiting, Australasian Myeloma Research Consortium
    New P2 trial
    |
    Elrexfio (elranatamab-bcmm)